GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Other Operating Expense

CMND (Clearmind Medicine) Other Operating Expense : $0.03 Mil (TTM As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Other Operating Expense?

Clearmind Medicine's Other Operating Expense for the three months ended in Jul. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jul. 2024 was $0.03 Mil.

Clearmind Medicine's quarterly Other Operating Expense increased from Jan. 2024 ($-0.00 Mil) to Apr. 2024 ($0.00 Mil) but then declined from Apr. 2024 ($0.00 Mil) to Jul. 2024 ($0.00 Mil).

Clearmind Medicine's annual Other Operating Expense increased from Oct. 2021 ($0.00 Mil) to Oct. 2022 ($0.05 Mil) but then declined from Oct. 2022 ($0.05 Mil) to Oct. 2023 ($0.03 Mil).


Clearmind Medicine Other Operating Expense Historical Data

The historical data trend for Clearmind Medicine's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Other Operating Expense Chart

Clearmind Medicine Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Other Operating Expense
Get a 7-Day Free Trial - - - 0.05 0.03

Clearmind Medicine Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 - - -

Clearmind Medicine Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clearmind Medicine Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearmind Medicine Business Description

Traded in Other Exchanges
Address
101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.